Pentadeca Arginate

Pentadeca Arginate (PDA) is the arginate salt form of the stable gastric pentadecapeptide BPC-157 (Body Protection Compound-157, bepecin, PL 14736), a synthetic 15-amino-acid oligopeptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and a molecular weight of 1419.55 daltons (free base). The parent peptide was first characterized by Sikiric and colleagues at the University of Zagreb in 1993 as a partial sequence of a protein isolated from human gastric juice, and it has since accumulated a preclinical literature of more than 100 peer-reviewed publications demonstrating cytoprotective, pro-angiogenic, anti-inflammatory, and tissue-regenerative activity across gastrointestinal, musculoskeletal, hepatic, cardiovascular, and central nervous system injury models. The arginate salt formulation replaces the conventional acetate counterion with L-arginine, producing two pharmacologically consequential changes: first, a marked improvement in structural stability under simulated gastric acid conditions (greater than 95 percent structural integrity after five hours of gastric acid exposure, compared to less than 2 percent for the acetate form); and second, a reported increase in oral bioavailability of approximately 7-fold relative to the acetate salt, attributed to the arginine shielding of the peptide backbone from enzymatic degradation and the concurrent delivery of L-arginine as a nitric oxide synthase substrate that complements the parent peptide's established nitric oxide system modulation. The pharmacology of Pentadeca Arginate is that of BPC-157, a pleiotropic cytoprotective agent whose principal characterized mechanisms include bidirectional modulation of nitric oxide production through the Akt-eNOS signaling axis; upregulation of vascular endothelial growth factor receptor 2 (VEGFR2), epidermal growth factor receptor (EGFR), and growth hormone receptor expression; activation of extracellular signal-regulated kinase (ERK1/2) pathways driving fibroblast proliferation and collagen deposition; modulation of dopaminergic, serotonergic, and GABAergic neurotransmitter systems; and activation of early response gene cascades (Egr1, Akt1, Src, Nos3) within minutes of tissue injury. Preclinical pharmacokinetic characterization in rats and beagle dogs (Xu et al. 2022) demonstrated rapid absorption after intramuscular administration (Tmax approximately 3 minutes in rats, 6 to 9 minutes in dogs), a short plasma elimination half-life (approximately 15 minutes in rats, approximately 5 minutes in dogs), linear pharmacokinetics across studied dose ranges, and rapid metabolism to constituent amino acids through normal peptide degradation pathways. Human pharmacokinetic data remain extremely limited. Clinical evidence for BPC-157 in humans is confined to three pilot studies encompassing fewer than 30 total participants: a Phase I safety study in healthy volunteers (Veljaca et al. 2003), a Phase II enema study in ulcerative colitis (Ruenzi et al., unpublished full data), and recent intravenous safety studies (Lee and Burgess 2024, Lee et al. 2025) that reported no adverse events or clinically meaningful changes in cardiac, hepatic, renal, thyroid, or metabolic biomarkers at doses up to 20 mg. BPC-157 is not approved by any drug regulatory agency for human use. In September 2023, the United States Food and Drug Administration classified BPC-157 as a Category 2 bulk drug substance, prohibiting its use in compounding by 503A and 503B pharmacies. The World Anti-Doping Agency banned BPC-157 in 2022 under the S0 category of non-exempt substances. Pentadeca Arginate emerged in the clinical and compounding pharmacy market as an alternative formulation following the FDA Category 2 classification, leveraging the arginate salt distinction. This monograph reviews the chemistry, synthesis, and salt-form pharmacology of Pentadeca Arginate; the comprehensive preclinical pharmacology of the parent BPC-157 peptide across gastrointestinal, musculoskeletal, vascular, and central nervous system models; the limited human clinical evidence; sourcing and quality considerations; reconstitution and handling; stack-interaction implications; the adverse-event and safety profile; and a comparative assessment of five tissue-regenerative peptide candidates against Pentadeca Arginate on five competency standards.